These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24936796)

  • 1. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.
    Kim YM; Lee SW; Chun SM; Kim DY; Kim JH; Kim KR; Kim YT; Nam JH; van Hummelen P; MacConaill LE; Hahn WC; Jang SJ
    PLoS One; 2014; 9(6):e99451. PubMed ID: 24936796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
    Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
    Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
    Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic alterations, metabolizing genes and smoking in rectal cancer.
    Curtin K; Samowitz WS; Wolff RK; Herrick J; Caan BJ; Slattery ML
    Int J Cancer; 2009 Jul; 125(1):158-64. PubMed ID: 19358278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia.
    Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
    World J Gastroenterol; 2013 Aug; 19(32):5286-94. PubMed ID: 23983431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
    Niskakoski A; Kaur S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Int J Cancer; 2013 Dec; 133(11):2596-608. PubMed ID: 23716351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.
    Matulonis UA; Hirsch M; Palescandolo E; Kim E; Liu J; van Hummelen P; MacConaill L; Drapkin R; Hahn WC
    PLoS One; 2011; 6(9):e24433. PubMed ID: 21931712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
    Nodin B; Zendehrokh N; Sundström M; Jirström K
    Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
    Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
    Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
    Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
    J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.
    Dobrzycka B; Terlikowski SJ; Kinalski M; Kowalczuk O; Niklinska W; Chyczewski L
    Ann Oncol; 2011 May; 22(5):1133-1140. PubMed ID: 21098618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
    Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
    Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
    Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
    Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.
    Donehower LA; Creighton CJ; Schultz N; Shinbrot E; Chang K; Gunaratne PH; Muzny D; Sander C; Hamilton SR; Gibbs RA; Wheeler D
    J Pathol; 2013 Jan; 229(1):99-110. PubMed ID: 22899370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.